Home » Commissioner Change Won't Affect FDA's Agenda, Observers Say
Commissioner Change Won't Affect FDA's Agenda, Observers Say
October 4, 2005
Acting FDA Commissioner Andrew von Eschenbach is unlikely to have much effect on the agency’s agenda, as the FDA’s existing division heads will continue to drive policy decisions, according to various stakeholders. However, these same sources said the continuous turnover in leadership at the FDA may tarnish the agency’s credibility.